Combination effect of cetuximab with radiation in colorectal cancer cells

作者: Hye Kyung Shin , Mi-Sook Kim , Jin Kyung Lee , Seung-Sook Lee , Young Hoon Ji

DOI: 10.1177/030089161009600513

关键词: Radiation therapyEpidermal growth factor receptorColorectal cancerOncologyRadiosensitivityMedicineTransplantationCetuximabEGFR inhibitorsInternal medicineRadiosensitizer

摘要: Aims and background. Colorectal cancer (CRC) is one of the commonest malignant disorders frequently associated with high expression epidermal growth factor receptor (EGFR), resulting in advanced disease a poor prognosis. In this study, we investigated radiosensitizing effects selective EGFR inhibitor cetuximab human CRC cell lines. Methods. Four lines, CaCo-2, HCT-8, LoVo, WiDr, were treated and/or radiation. The on proliferation viability measured by MTT annexin-V staining, clonogenic survival assay. vivo effect xenografts was assessed athymic nude mice. Results. Cetuximab combination radiation significantly inhibited vitro cells, concomitant increase death, except WiDr cells. Clonogenic assay confirmed that worked as radiosensitizer three cetuximab-sensitivie However, no correlations found between radiosensitivity level or mutation status signaling molecules. mice bearing xenografts, plus tumor over either agent alone. Interestingly, xenograft also sensitive to vivo, suggesting host-mediated cetuximab. Conclusions. enhanced cells efficiently growth. This study provided rationale for clinical application CRC. Free full text available at www.tumorionline.it.

参考文章(47)
Tania Crombet Ramos, Javier Figueredo, Mauricio Catala, González Sandra, Julio C Selva, Tania M Cruz, Carolina Toledo, Sergio Silva, Yanet Pestano, Mayra Ramos, Idrissa Leonard, Olga Torres, Patricia Marinello, Rolando Pérez, Agustín Lage, None, Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biology & Therapy. ,vol. 5, pp. 375- 379 ,(2006) , 10.4161/CBT.5.4.2522
Minaxi Jhawer, Sanjay Goel, Andrew J. Wilson, Cristina Montagna, Yi-He Ling, Do-Sun Byun, Shannon Nasser, Diego Arango, Joongho Shin, Lidija Klampfer, Leonard H. Augenlicht, Roman Perez Soler, John M. Mariadason, PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab Cancer Research. ,vol. 68, pp. 1953- 1961 ,(2008) , 10.1158/0008-5472.CAN-07-5659
A Diaz Miqueli, J Rolff, M Lemm, I Fichtner, R Perez, E Montero, Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies British Journal of Cancer. ,vol. 100, pp. 950- 958 ,(2009) , 10.1038/SJ.BJC.6604943
Michael J. Overman, Paulo M. Hoff, EGFR-Targeted Therapies in Colorectal Cancer Diseases of The Colon & Rectum. ,vol. 50, pp. 1259- 1270 ,(2007) , 10.1007/S10350-007-0228-3
Mario Scartozzi, Italo Bearzi, Rossana Berardi, Alessandra Mandolesi, Guidalberto Fabris, Stefano Cascinu, Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted Monoclonal Antibodies Journal of Clinical Oncology. ,vol. 22, pp. 4772- 4778 ,(2004) , 10.1200/JCO.2004.00.117
Daniel J. Hicklin, Lee M. Ellis, Harlan W. Waksal, Andrea T. Hooper, Marie C. Prewett, Rajiv Bassi, Enhanced Antitumor Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody IMC-C225 in Combination with Irinotecan (CPT-11) against Human Colorectal Tumor Xenografts Clinical Cancer Research. ,vol. 8, pp. 994- 1003 ,(2002)
Tania Crombet-Ramos, Janusz Rak, Rolando Pérez, Alicia Viloria-Petit, Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. International Journal of Cancer. ,vol. 101, pp. 567- 575 ,(2002) , 10.1002/IJC.10647